Pharma-Bio Service提高了2025年的收入和收入,说明制造业表现强劲,并宣布2026年3月的特别红利为1.25美元。 Pharma-Bio Serv boosted 2025 revenue and earnings, citing strong manufacturing performance and declaring a $1.25 special dividend for March 2026.

Pharma-Bio Service报告了2025年全年的成果,表明收入增加,每股收入得到调整,其驱动因素是制药部门表现强劲。 Pharma-Bio Serv reported full-year 2025 results, showing increased revenue and adjusted earnings per share, driven by strong performance in its pharmaceutical manufacturing segment. 该公司还宣布特别红利为每股1.25美元,应于2026年3月支付,理由是现金流和财政稳定。 The company also declared a special dividend of $1.25 per share, payable in March 2026, citing strong cash flow and financial stability. 管理层对能力扩大和新产品开发方面持续投资的持续增长表示有信心。 Management expressed confidence in continued growth amid ongoing investments in capacity expansion and new product development.